Pre-made Obrindatamab benchmark antibody ( Bispecific scFv with Domain Crossover, anti-CD276;CD3E therapeutic antibody, Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Obrindatamab biosimilar, Bispecific scFv with Domain Crossover, Anti-CD276;CD3E Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Obrindatamab (formerly orlotamab) was a Fc-bearing humanised bispecific dual-affinity re-targeting (DART) protein, that was being developed by MacroGenics for the treatment of solid tumours.
| Products Name (INN Index) | Pre-Made Obrindatamab biosimilar, Bispecific scFv with Domain Crossover, Anti-CD276;CD3E Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 therapeutic antibody |
|---|---|
| INN Name | Obrindatamab |
| Target | CD276,CD3E |
| Format | Bispecific scFv with Domain Crossover |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | na;na |
| VD LC | Kappa,Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | MacroGenics |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Advanced or Metastatic solid tumours |
| Development Tech | Dual-Affinity?Re-targenting (DART?) |
| Previous Name | NA |
| Gm Offical Target Name | CD276,CD3E |
| Package |
